Amgen Inc (AMGN : NASDAQ)
Common Stock
$27.77
USD
-348.58 (-92.62%)
Last updated: 2026-09-17
Get AMGN alerts:
AMGN
Amgen Inc
WealthAwesomePerformance
1 Day
+0.19%
1 Week
-3.81%
1 Month
-9.74%
YTD
+10.80%
Key Statistics
Market Cap
$203.47B
52W High
$447.03
52W Low
$262.49
P/E Ratio
23.30
50 Day MA
$399.60
200 Day MA
$359.94
Beta
0.43
Dividend Yield
2.61%
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $379.15 | $382.49 | $376.08 | $379.78 | $379.78 | 3,234,953 |
| 9/16/2026 | $377.01 | $379.11 | $374.46 | $376.35 | $376.35 | 2,401,881 |
| 9/15/2026 | $380.23 | $381.04 | $375.15 | $375.65 | $375.65 | 2,609,000 |
| 9/14/2026 | $381.94 | $384.61 | $376.76 | $381.50 | $381.50 | 2,714,400 |
| 9/11/2026 | $386.14 | $386.99 | $377.22 | $377.35 | $377.35 | 2,272,400 |
| 9/10/2026 | $387.84 | $391.67 | $381.51 | $382.47 | $382.47 | 3,430,900 |
| 9/9/2026 | $393.07 | $395.55 | $389.28 | $391.27 | $391.27 | 2,921,400 |
| 9/8/2026 | $408.90 | $410.03 | $391.17 | $393.17 | $393.17 | 6,825,100 |
| 9/4/2026 | $437.03 | $441.85 | $435.00 | $437.23 | $437.23 | 1,648,800 |
| 9/3/2026 | $445.67 | $445.82 | $438.08 | $444.12 | $444.12 | 1,842,300 |
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 17, 2026
Wall Street analysts forecast AMGN stock price to rise 1297.3% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
US$388.03
+1297.3% Upside
Current Price
US$27.77
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
38.0%
Annualized
90-Day Vol
33.1%
Annualized
Trend (90d)
+40.3%
Annualized drift
90d Mean
US$438.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$398.47 | US$349.55 – US$454.23 |
| 60 trading days | US$418.07 | US$347.38 – US$503.16 |
| 90 trading days | US$438.65 | US$349.61 – US$550.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Financials
- Revenue (TTM)
- $38.09B
- EBITDA
- $17.27B
- Profit Margin
- 22.95%
- ROE (TTM)
- 91.47%
- EPS (Diluted)
- 16.15
- Book Value
- 21.62
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About AMGN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |
AMGN.US news timeline
9 articles covering AMGN.US, most recent first
Latest